By Fineline Cube Changchun High & New Tech (SHE: 000661) announced it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for GenSci164, an investigational PTH1R agonist developed for the treatment of hypoparathyroidism (HP). The drug candidate leverages GenSci’s proprietary Duratide long-acting, sustained-release peptide technology to address a significant unmet medical need in calcium and phosphorus metabolism disorders.
Clinical Development Overview
| Item | Detail |
|---|---|
| Company | Changchun High & New Tech (SHE: 000661) |
| Drug Candidate | GenSci164 |
| Classification | Therapeutic Biological-1 product |
| Target Indication | Hypoparathyroidism (HP) |
| Regulatory Milestone | NMPA clinical trial approval |
| Approval Date | 04 Jul 2026 |
| Development Stage | Pre-clinical to Phase I transition |
Drug Profile & Mechanism of Action
- Molecule Type: PTH1R agonist (parathyroid hormone receptor 1 agonist)
- Technology Platform: Duratide – proprietary long-acting, sustained-release peptide technology
- Structural Innovation: Novel and unique structural design combined with extended-release mechanism
- Pharmacokinetic Advantage: Significantly extended half-life of active peptide in vivo compared to conventional PTH analogs
- Therapeutic Mechanism: Regulates calcium and phosphorus metabolism by:
- Increasing blood calcium levels
- Lowering blood phosphorus levels
- Restoring both parameters to normal physiological range
Market Opportunity & Unmet Need
- Hypoparathyroidism Landscape: Rare endocrine disorder affecting approximately 37-70 per 100,000 individuals globally, characterized by insufficient parathyroid hormone production
- Current Treatment Limitations: Standard therapy relies on high-dose calcium and active vitamin D supplements, which fail to fully normalize calcium-phosphorus homeostasis and carry risks of long-term complications including renal impairment and ectopic calcification
- Competitive Differentiation: GenSci164 represents a physiologic replacement approach that mimics natural PTH function, potentially offering superior metabolic control compared to symptomatic management
- Commercial Potential: First-in-class PTH1R agonist with extended half-life could command premium pricing in orphan drug markets across China, Asia-Pacific, and potentially global territories
Strategic Implications
- Platform Validation: Successful development of GenSci164 would validate GenSci’s Duratide technology platform for other peptide-based therapeutics requiring sustained release profiles
- Orphan Drug Designation: Likely eligible for orphan drug incentives in multiple jurisdictions, providing market exclusivity and development support
- Pipeline Expansion: Demonstrates Changchun High & New Tech’s commitment to expanding beyond traditional biologics into specialized endocrine disorders
- Partnership Potential: Strong clinical data could attract international partnership interest for ex-China development and commercialization rights
The NMPA clinical approval marks a critical milestone in advancing GenSci164 toward addressing the fundamental pathophysiology of hypoparathyroidism rather than merely managing its symptoms, potentially establishing a new standard of care for HP patients.-Fineline Info & Tech